Importance of molecular genetics of sarcomas

Cancer Forum

Volumn 34, Issue 3, 2010, Pages 154-156

  Thomas, David M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER GENETICS; DERMATOFIBROSARCOMA PROTUBERANS; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE SYSTEM; HISTIOCYTOMA; HISTOPATHOLOGY; HUMAN; LIPOSARCOMA; MOLECULAR GENETICS; OSTEOSARCOMA; SARCOMA; SHORT SURVEY;

EID: 78649395548     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Australian Institute of Health and Welfare Cancer Data Cubes [Internet]. Available from: http.//www.aihw.gov.au/cancer/data/index.cfm [cited 2010 September 20]
2. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies paradox or paradigm? Mol Cancer Ther. 2007;6:1175-1179.
3. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314:268-274.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
5. Fletcher DM, Unni KK, Mertens F; World Health Organization Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon. IARC Press,2002.
6. Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045-3050.
7. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998;279:577-580.
8. Cassier PA, Ducimetière F, Lurkin A, Ranchère-Vince D, Scoazec JY, Bringuier PP, Decouvelaere AV, Méeus P, Cellier D, Blay JY, Ray-Coquard I A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010; 103:165-70.
9. Moore M, Desai J. New Drugs in the Management of Sarcoma. Cancer Forum 2010; 157-163.
10. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
11. Thomas DM, Wagner AJ. Specific targets in sarcoma and developmental therapeutics. J Natl Compr Canc Netw. 2010;(8,quiz 686):677-685.
12. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al.Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
13. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.